Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock

Reuters07-28

Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock

Impact BioMedical Inc. has announced a significant financial restructuring through a Debt Conversion Agreement with DSS, Inc. The agreement involves the conversion of an outstanding loan, originally valued at $12 million, into common stock. Under the terms of the agreement, Impact BioMedical will issue 31,939,778 shares of its common stock to DSS, effectively settling the debt in full. The original loan, which was subject to amendments including a revised interest rate of WSJ Prime + 0.5%, will be entirely satisfied with this conversion. This strategic move aims to strengthen Impact BioMedical's financial position by reducing its debt obligations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Biomedical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-021085), on July 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2554702687?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-28 23:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554702687","market":"nz","top_or_hot":-1,"title":"Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Impact BioMedical Inc. has announced a significant financial restructuring through a Debt Conversion Agreement with DSS, Inc. The agreement involves the conversion of an outstanding loan, originally valued at $12 million, into common stock. Under the terms of the agreement, Impact BioMedical will issue 31,939,778 shares of its common stock to DSS, effectively settling the debt in full. The original loan, which was subject to amendments including a revised interest rate of WSJ Prime + 0.5%, will be entirely satisfied with this conversion. This strategic move aims to strengthen Impact BioMedical's financial position by reducing its debt obligations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IBO\">Impact Biomedical</a> Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-021085), on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImpact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-28 23:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Impact BioMedical Inc. has announced a significant financial restructuring through a Debt Conversion Agreement with DSS, Inc. The agreement involves the conversion of an outstanding loan, originally valued at $12 million, into common stock. Under the terms of the agreement, Impact BioMedical will issue 31,939,778 shares of its common stock to DSS, effectively settling the debt in full. The original loan, which was subject to amendments including a revised interest rate of WSJ Prime + 0.5%, will be entirely satisfied with this conversion. This strategic move aims to strengthen Impact BioMedical's financial position by reducing its debt obligations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IBO\">Impact Biomedical</a> Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-021085), on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DSS","symbol_name":"DSS Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDLlyJpC:1","article_id":"2554702687","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554702687","pubTimestamp":1753715168,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock. Impact BioMedical Inc. has announced a significant financial restructuring through a Debt Conversion Agreement with DSS, Inc. The agreement involves the conversion of an outstanding loan, originally valued at $12 million, into common stock. Under the terms of the agreement, Impact BioMedical will issue 31,939,778 shares of its common stock to DSS, effectively settling the debt in full. The original loan, which was subject to amendments including a revised interest rate of WSJ Prime + 0.5%, will be entirely satisfied with this conversion. This strategic move aims to strengthen Impact BioMedical's financial position by reducing its debt obligations.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DSS":"DSS Inc","BK4563":"昨日强势股","BK4087":"商业印刷","BK4024":"房地产开发","IBO":"Impact Biomedical, Inc.","BK4007":"制药","AEI":"Alset EHome International Inc."},"translate_title":"Impact BioMedical Inc.宣布债务转换协议，通过发行普通股与DSS，Inc.解决1200万美元贷款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBO":0.9,"DSS":0.9,"AEI":0.9},"content_text":"Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock\n    \n\n        Impact BioMedical Inc. has announced a significant financial restructuring through a Debt Conversion Agreement with DSS, Inc. The agreement involves the conversion of an outstanding loan, originally valued at $12 million, into common stock. Under the terms of the agreement, Impact BioMedical will issue 31,939,778 shares of its common stock to DSS, effectively settling the debt in full. The original loan, which was subject to amendments including a revised interest rate of WSJ Prime + 0.5%, will be entirely satisfied with this conversion. This strategic move aims to strengthen Impact BioMedical's financial position by reducing its debt obligations.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Biomedical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-021085), on July 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2554702687","isCrawlerRequest":true}